Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senl-T7 in Relapsed/Refractory CD7+ T-ALL and T-LBL
NCT05626400Phase 1Recruiting
- Sponsor
- Senlang Bio
- Start
- Aug 2022
- Primary completion
- Oct 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SENL101 in t-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL), sponsored by Senlang Bio. Primary endpoints: Incidence and severity of adverse events at 1 month and Remission Rate at 3 months. Started Aug 2022; status: recruiting.
02
Drugs
SENL101
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT05626400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05626400.